文献速递药物不良反应与药物警戒

越南药物警戒体系概览:资源受限国家的经验与启示

Overview of Pharmacovigilance System in Vietnam: Lessons Learned in a Resource-Restricted Country.
PubMed 文献 · Drug Saf · 2018-01-01

本文介绍越南2009年成立的大学附属国家药物信息与不良反应监测中心(NDIADRMC)的药物警戒体系发展情况。该中心虽资源有限,但已基本达到世界卫生组织对功能性药物警戒中心的最低要求,报告数量快速增长并产生重要信号,但报告质量、风险评估与沟通仍有限,需加强内外部支持以完善体系。

要点

  • 越南药物警戒体系依托大学建立国家中心,已基本满足WHO最低要求。
  • 报告数量快速增长,部分信号已转化为国家层面监管行动。
  • 报告质量、风险评估与沟通仍有限,需加强风险沟通与效果评估。

核心结论

  • 越南药物警戒体系在资源受限条件下取得初步成效,但报告质量、风险评估与沟通仍有限,需更多内外部支持以完善体系。

研究设计与样本

  • 本文为越南药物警戒体系的综述性概述,介绍其国家药物信息与不良反应监测中心(NDIADRMC)的建立与运行情况。

主要发现

  • NDIADRMC于2009年启动,已基本达到世界卫生组织对功能性药物警戒中心的最低要求。
  • 报告数量快速增长,部分重要信号已促成国家层面监管行动。
  • 该系统有助于发现发达国家较少见的药品质量问题。
  • 与更发达体系相比,报告数量与质量、风险评估及沟通仍有限。

临床怎么用

  • 资源受限国家可借鉴越南模式,依托大学建立国家药物警戒中心并逐步达到WHO最低要求。
  • 应重视报告数量增长后的信号挖掘与监管转化,同时加强风险沟通与药物警戒效果评估。

局限性

  • 文章为体系概述,未报告具体报告数量、质量指标或风险评估的量化数据。
  • 未涉及药物警戒干预对药品相关风险降低效果的量化评价。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug safety issues in developing countries are complex and sensitive, and health authorities cannot always simply implement decisions from developed countries because the health system, disease patterns, and lists of marketed drugs all differ. A system for proactive and effective surveillance of drugs in each nation is needed to identify and manage the exact drug-related problems faced by patients in these countries. Vietnam launched its university-based National Drug Information and Adverse Drug Reaction Monitoring Centre (NDIADRMC) in 2009, a significant step towards catching up with international trends. Although the center is still in its infancy and has limited resources, it has attained some achievements and largely met the minimum World Health Organization requirements for a functional pharmacovigilance center. The number of reports has increased rapidly, with some important signals generated from the national database leading to regulatory actions at a national level. In addition, this system can help detect drug-quality problems that are less common in developed countries. The success of the quantity and quality of reporting, risk assessment, and communication is still limited compared with more developed systems. A number of opportunities remain to enhance the system, particularly in risk communication and evaluation of the impact of pharmacovigilance, and to apply reporting outcomes to reduce drug-related risks throughout the country. More internal and external support is needed to develop a stronger and more comprehensive pharmacovigilance system.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Nguyen KD, Nguyen PT, Nguyen HA, et al. Overview of Pharmacovigilance System in Vietnam: Lessons Learned in a Resource-Restricted Country. Drug Saf. 2018. PMID: 28975584. doi:10.1007/s40264-017-0598-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。